Supplementary Figure Legends from Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition

PDF file - 116KB</p

Supplementary Figures 1 - 3, Tables 1 - 3 from Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition

PDF file - 1325KB, Caption Supplementary Figure 1 A and 1B. The combined treatment of cetuximab and the selective MEK1/2 inhibitor BAY 86-9766 induce a synergistic growth inhibitory effects in CRC cell lines with primary and acquired resistance to cetuximab and an antagonistic effects in cetuximab-sensitive CRC cell lines. Caption Supplementary Figure 2. The BAY 86-9766 treatment, in CRC cancer cell lines with primary and acquired resistance to cetuximab, induce a dose dependent reduction of MAPK and MEK phosphorylation. Caption Supplementary Figure 3. The combined treatment of cetuximab and the selective MEK1/2 inhibitor BAY 86-9766 was well tolerated by mice, with no weight loss or other signs of acute or delayed toxicity. Caption Supplementary Table 1A and 1B. The panel of CRC cell lines have been treated with several concentrations of cetuximab and selective MEK1/2 inhibitors (BAY 86-9766, Selumetinib and Pimasertib), showing differential sensitivity to the drugs. Caption Supplementary Table 2. We have performed the experiments on a panel of eight human CRC cell lines having different mutation profiles in KRAS, NRAS, BRAF, PIK3CA and EGFR genes. Caption Supplementary Table 3. In the CRC cell lines with acquired and primary resistance to cetuximab, the treatment with the selective MEK1/2 inhibitor BAY 86-9766 determined synergistic growth inhibitory effects in combination with cetuximab.</p

Additional file 2: of Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models

Table S1. Evaluation of protein expression level in parental (SW48 and LIM1215) and in HER2-amplified human colon cancer cell lines. Legend: Negative symbol (-) no protein expression detected; Positive symbols: (+) expression and (++) over-expression levels of each protein detected. Table S2. Antitumor efficacy of oxaliplatin plus trastuzumab followed by maintenance treatment in human HER2-amplified colon cancer xenograft. (DOCX 613 kb

Additional file 1: of Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models

Figure S1. Expression and phosphorylation of HER2 in parental SW48 and LIM1215 human colon cancer cell lines and in their HER2-amplified derivatives (SW48-HER2 and LIM1215-HER2) cells (Additional file 3: Supplementary Methods). Figure S2. Phenotypic characterization of parental SW48 and LIM1215 human colon cancer cell lines and of their HER2-amplified derivatives (SW48-HER2 and LIM1215-HER2) cells. Figure S3. Expression and phosphorylation of HER family receptors and their downstream signaling pathways in parental SW48 and LIM1215 human colon cancer cell lines and in their HER2-amplified derivatives (SW48-HER2 and LIM1215-HER2) cells. Figure S4. Effects of chemotherapeutic agents and of anti-EGFR monoclonal antibodies on cell proliferation in parental SW48 and LIM1215 human colon cancer cell lines and in their HER2-amplified derivatives (SW48-HER2 and LIM1215-HER2) cells. (DOCX 5258 kb

Additional file 3: of Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models

Supplementary Methods. (DOCX 18 kb

Additional file 4 of Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial

Additional file 4

sj-pptx-3-tam-10.1177_17588359221096878 – Supplemental material for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience

Supplemental material, sj-pptx-3-tam-10.1177_17588359221096878 for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience by Vincenza Caputo, Vincenzo De Falco, Anna Ventriglia, Vincenzo Famiglietti, Erika Martinelli, Floriana Morgillo, Giulia Martini, Carminia Maria Della Corte, Davide Ciardiello, Luca Poliero, Ferdinando De Vita, Michele Orditura, Morena Fasano, Renato Franco, Michele Caraglia, Arianna Avitabile, Roberto Scalamogna, Beatrice Marchi, Fortunato Ciardiello, Teresa Troiani and Stefania Napolitano in Therapeutic Advances in Medical Oncology</p

sj-pptx-5-tam-10.1177_17588359221096878 – Supplemental material for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience

Supplemental material, sj-pptx-5-tam-10.1177_17588359221096878 for Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience by Vincenza Caputo, Vincenzo De Falco, Anna Ventriglia, Vincenzo Famiglietti, Erika Martinelli, Floriana Morgillo, Giulia Martini, Carminia Maria Della Corte, Davide Ciardiello, Luca Poliero, Ferdinando De Vita, Michele Orditura, Morena Fasano, Renato Franco, Michele Caraglia, Arianna Avitabile, Roberto Scalamogna, Beatrice Marchi, Fortunato Ciardiello, Teresa Troiani and Stefania Napolitano in Therapeutic Advances in Medical Oncology</p

Additional file 1 of Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial

Additional file 1

Additional file 3 of Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial

Additional file 3